<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01672775</url>
  </required_header>
  <id_info>
    <org_study_id>AGS-16C3F-12-2</org_study_id>
    <nct_id>NCT01672775</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology</brief_title>
  <official_title>A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agensys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics and assess the&#xD;
      immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has two components. The first aims to establish a safe dose for AGS-16C3F. Once&#xD;
      identified, the safety and effectiveness will be tested in additional subjects with either&#xD;
      clear cell or papillary histology in expanded cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2012</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">February 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile for total antibody (TAb), antibody drug conjugate (ADC), and monomethyl auristatin F (MMAF): Ceoi or Cmax, Ctrough, Tmax, AUCτ, t1/2, CL, and Vss</measure>
    <time_frame>Days 1, 2, 3, 4, 8, 15, 22, 43, 64, 65, 66, 67, 71, 78, and 92</time_frame>
    <description>Concentration at end of infusion (Ceoi) or maximum observed concentrations (Cmax), Trough concentration (Ctrough), time to maximum concentration (Tmax), partial area under the serum concentration-time curve (AUCτ), terminal or apparent half-life (t1/2), systemic clearance (CL), and volume of distribution at steady state (Vss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antidrug antibody formation to human native antibody (AGS-16C) and antibody drug conjugate (AGS-16C3F)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: objective response rate</measure>
    <time_frame>24 months</time_frame>
    <description>Determined from the subjects' best response and will include complete response (CR) and partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: disease control rate</measure>
    <time_frame>24 months</time_frame>
    <description>Determined from the subjects' best response will include complete response (CR) partial response (PR), and stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: Changes in bone scans</measure>
    <time_frame>Baseline, Week 13 and every 12 weeks thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Renal Cell Carcinoma of Papillary Histology</condition>
  <condition>Renal Cell Carcinoma With Clear Cell Histology</condition>
  <condition>Renal Cell Carcinoma With Non-Clear Cell Histology</condition>
  <arm_group>
    <arm_group_label>Cohort 1 AGS-16C3F highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma subjects with clear and non-clear histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 0 AGS-16C3F higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma subjects with clear and non-clear histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort (-1) AGS-16C3F high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma subjects with clear and non-clear histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort (-2) AGS-16C3F middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma subjects with clear and non-clear histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort (-3) AGS-16C3F low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma subjects with clear and non-clear histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort (-4) AGS-16C3F lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma subjects with clear and non-clear histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-16C3F in RCC Subjects with Clear Cell Histology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-16C3F in RCC Subjects with Papillary Histology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGS-16C3F</intervention_name>
    <description>intravenous (IV) infusion</description>
    <arm_group_label>AGS-16C3F in RCC Subjects with Clear Cell Histology</arm_group_label>
    <arm_group_label>AGS-16C3F in RCC Subjects with Papillary Histology</arm_group_label>
    <arm_group_label>Cohort (-1) AGS-16C3F high dose</arm_group_label>
    <arm_group_label>Cohort (-2) AGS-16C3F middle dose</arm_group_label>
    <arm_group_label>Cohort (-3) AGS-16C3F low dose</arm_group_label>
    <arm_group_label>Cohort (-4) AGS-16C3F lowest dose</arm_group_label>
    <arm_group_label>Cohort 0 AGS-16C3F higher dose</arm_group_label>
    <arm_group_label>Cohort 1 AGS-16C3F highest dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dose determination cohorts: Histologically confirmed diagnosis of metastatic RCC of&#xD;
             either clear cell or non-clear histology.&#xD;
&#xD;
               -  Tumors with clear cell histology: subject must have progressed after at least one&#xD;
                  anti-vascular endothelial growth factor receptor (anti-VEGFR) therapy&#xD;
&#xD;
               -  Tumors with non-clear cell histology must be ectonucleotide&#xD;
                  pyrophosphatase/phosphodiesterase family member 3 (ENPP3) positive at&#xD;
                  pre-screening. This sub-group does not have any prior therapy requirement.&#xD;
&#xD;
          -  Dose expansion cohorts: Histologically confirmed diagnosis of metastatic RCC of either&#xD;
             clear cell or papillary histology&#xD;
&#xD;
               -  Tumors with clear cell histology: subject must have progressed after at least one&#xD;
                  anti-VEGFR therapy&#xD;
&#xD;
               -  Tumors with papillary histology: includes unclassified histology with papillary&#xD;
                  features and must be ENPP3 positive at pre-screening. This sub-group does not&#xD;
                  have any prior therapy requirement.&#xD;
&#xD;
          -  Measurable disease according to Response Criteria for Solid Tumors (RECIST Version&#xD;
             1.1)&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Hematologic function, as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL (transfusions are allowed)&#xD;
&#xD;
          -  Renal function, as follows:&#xD;
&#xD;
               -  creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular&#xD;
                  filtration rate (GFR) &gt; 50 mL/min if creatinine &gt; 1.5x ULN&#xD;
&#xD;
          -  Hepatic function, as follows:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
                  or ≤ 5x ULN if known liver metastases&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x ULN&#xD;
&#xD;
          -  International normalized ratio (INR) &lt; 1.3 (or ≤ 3.0 if on therapeutic&#xD;
             anticoagulation)&#xD;
&#xD;
          -  Women and men of childbearing potential must be advised and agree to practice&#xD;
             effective methods of contraception during the course of the study and for 4 weeks&#xD;
             after the last AGS-16C3F infusion administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors&#xD;
&#xD;
          -  Use of any investigational drug (including marketed drugs not approved for this&#xD;
             indication) within 4 weeks prior to screening. No time limit applies to the use of&#xD;
             marketed drugs approved for this indication provided that the subject has progressed&#xD;
             on the treatment and all toxicities attributable to the drug have resolved or returned&#xD;
             to baseline&#xD;
&#xD;
          -  Known sensitivity to any of the ingredients of the investigational product AGS-16C3F&#xD;
&#xD;
          -  History of thromboembolic events and bleeding disorders ≤3 months (e.g., (deep vein&#xD;
             thrombosis) DVT or pulmonary embolism (PE))&#xD;
&#xD;
          -  Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart&#xD;
             Association CHF Functional Classification System) or clinically significant cardiac&#xD;
             disease within 12 months of study enrollment, including myocardial infarction,&#xD;
             unstable angina, grade 2 or greater peripheral vascular disease, congestive heart&#xD;
             failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient&#xD;
             medication.&#xD;
&#xD;
          -  Major surgery within 4 weeks of study enrollment&#xD;
&#xD;
          -  Women who are pregnant (confirmed by positive pregnancy test) or lactating&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis&#xD;
             B surface antigen.&#xD;
&#xD;
          -  Active infection requiring treatment with systemic (intravenous or oral)&#xD;
             anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of&#xD;
             screening.&#xD;
&#xD;
          -  History of eye surgery within 6 months, presence of cataracts or other ocular&#xD;
             disorders significantly affecting vision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Agensys, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US00005 University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US00003 Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US00004 Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US00002 Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US00001 Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA00006 Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA00008 British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA00009 London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA00007 Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/patientStudySearch.aspx?RID=;;;AGS-16C3F-12-2</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>August 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2012</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>AGS-16C3F</keyword>
  <keyword>Pharmacokinetics of AGS-16C3F</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

